
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems is viewed positively because 3Q26 results showed the core U.S. business reaccelerating, with U.S. revenue up 5% sequentially and total revenue of $207M beating estimates while adjusted EBITDA of $38M and EPS of $0.14 also exceeded expectations. Management’s initial 2027 guidance for low-single-digit revenue growth appears prudently conservative given easing coding and reimbursement headwinds, a final 2027 CMS rate increase for CPT 64582 in facility fees, and growth support from pulse generator replacements and incremental commercial investment funded by Project Horizon savings. The stock also looks attractive fundamentally because shares trade at about a 50% discount to peers on EV/2026 EBITDA and a roughly 33% discount to its own two-year median, despite a strong balance sheet with net cash above 25% of market cap and robust free cash flow generation.
Bears say
Inspire Medical Systems is facing a weakening fundamental backdrop as growth is expected to decelerate and even decline in 2026 amid coding and reimbursement frictions that are limiting profitability expansion. The 1Q guidance cut reduced confidence in management’s ability to outperform expectations, with reimbursement and coding confusion clouding visibility on demand and procedure economics. Additional pressure comes from the risk of earlier-than-expected competitive neurostimulation entrants, alternative OSA treatments, weight-loss drugs shrinking the addressable market, and possible delays or setbacks in the INSP V launch.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Inspire Medical Systems Inc (INSP) Forecast
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares